Forte Biosciences Appoints New Officers, Director Departs
Ticker: FBRX · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1419041
Sentiment: neutral
Topics: executive-changes, board-changes, appointments, compensation
TL;DR
Forte Bio shuffles execs: Roth out, Hastings (CMO) & Smith (CSO) in. New comp plans filed.
AI Summary
On August 20, 2024, Forte Biosciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of director Dr. Jonathan S. Roth, effective August 15, 2024. Additionally, the company appointed Dr. Paul J. Hastings as Chief Medical Officer and Dr. David M. R. Smith as Chief Scientific Officer, both effective August 20, 2024. The filing also disclosed compensatory arrangements for these officers.
Why It Matters
The appointment of new key officers in medical and scientific roles suggests a strategic shift or expansion in Forte Biosciences' research and development efforts. The departure of a director may indicate changes in board oversight or strategy.
Risk Assessment
Risk Level: medium — Changes in key leadership and compensatory arrangements can signal strategic shifts or internal challenges that may impact the company's future performance.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Dr. Jonathan S. Roth (person) — Departing Director
- Dr. Paul J. Hastings (person) — Appointed Chief Medical Officer
- Dr. David M. R. Smith (person) — Appointed Chief Scientific Officer
- August 20, 2024 (date) — Effective date of new officer appointments
- August 15, 2024 (date) — Effective date of director's departure
FAQ
Who has departed from the board of directors at Forte Biosciences?
Dr. Jonathan S. Roth has departed from the board of directors, with his departure being effective August 15, 2024.
What new executive positions have been filled at Forte Biosciences?
Dr. Paul J. Hastings has been appointed as Chief Medical Officer, and Dr. David M. R. Smith has been appointed as Chief Scientific Officer.
When were the new executive appointments effective?
The appointments of Dr. Paul J. Hastings as Chief Medical Officer and Dr. David M. R. Smith as Chief Scientific Officer were both effective August 20, 2024.
What specific items are covered in the 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, submission of matters to a vote of security holders, Regulation FD Disclosure, and financial statements and exhibits.
What is the former name of Forte Biosciences, Inc.?
The former name of Forte Biosciences, Inc. was Tocagen Inc., with a date of name change on November 20, 2007.
Filing Stats: 1,515 words · 6 min read · ~5 pages · Grade level 11.8 · Accepted 2024-08-22 16:05:32
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d888554d8k.htm (8-K) — 48KB
- d888554dex101.htm (EX-10.1) — 87KB
- 0001193125-24-205350.txt ( ) — 282KB
- fbrx-20240820.xsd (EX-101.SCH) — 3KB
- fbrx-20240820_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240820_pre.xml (EX-101.PRE) — 11KB
- d888554d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Amended and Restated 2021 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: August 22, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer